Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Change in Cash: 2023-2025

Historic Change in Cash for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to $138.9 million.

  • Monte Rosa Therapeutics' Change in Cash rose 728.35% to $138.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.8 million, marking a year-over-year increase of 23.77%. This contributed to the annual value of $96.4 million for FY2024, which is 33.03% up from last year.
  • According to the latest figures from Q3 2025, Monte Rosa Therapeutics' Change in Cash is $138.9 million, which was up 1,638.19% from -$9.0 million recorded in Q2 2025.
  • In the past 5 years, Monte Rosa Therapeutics' Change in Cash ranged from a high of $138.9 million in Q3 2025 and a low of -$145.7 million during Q1 2025.
  • Moreover, its 3-year median value for Change in Cash was $9.1 million (2024), whereas its average is $13.9 million.
  • As far as peak fluctuations go, Monte Rosa Therapeutics' Change in Cash plummeted by 816.59% in 2024, and later skyrocketed by 728.35% in 2025.
  • Over the past 3 years, Monte Rosa Therapeutics' Change in Cash (Quarterly) stood at $69.1 million in 2023, then spiked by 42.73% to $98.6 million in 2024, then soared by 728.35% to $138.9 million in 2025.
  • Its Change in Cash was $138.9 million in Q3 2025, compared to -$9.0 million in Q2 2025 and -$145.7 million in Q1 2025.